Dopamine receptors in the basal ganglia: relevance to Parkinson's disease.
At least five receptors for dopamine (D1-D5) have been recognised from molecular biological studies, and their pharmacological properties and brain localisations have been determined. The D1 and D2 subtypes are the principal subtypes in brain, and their cellular localisations in the caudate nucleus and putamen have been determined. With recent advances in the understanding of basal ganglia neuronal function, these localisation data enable insights into the mode of action of drugs used at present and in the future to treat Parkinson's disease.
Strange
P G
PG
Biological Laboratory, The University, Canterbury, Kent, U.K.
D001479:Basal Ganglia / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology*; D001480:Basal Ganglia Diseases / Q000188:drug therapy / Q000503:physiopathology; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology*; D003024:Clozapine / Q000378:metabolism; D015259:Dopamine Agents / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use; D065127:Dopamine D2 Receptor Antagonists; D005260:Female; D006220:Haloperidol / Q000378:metabolism; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D017072:Neostriatum / Q000187:drug effects / Q000378:metabolism; D009434:Neural Pathways / Q000378:metabolism / Q000503:physiopathology; D010300:Parkinson Disease / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*; D017447:Receptors, Dopamine D1 / Q000037:antagonists & inhibitors / Q000502:physiology*; D017448:Receptors, Dopamine D2 / Q000502:physiology*; D013469:Sulpiride / Q000378:metabolism
D015259:Dopamine Agents; D065127:Dopamine D2 Receptor Antagonists; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D007980:Levodopa; D013469:Sulpiride; D003024:Clozapine; D006220:Haloperidol